Based on Phase 2 trial data (Jastreboff et al., NEJM , 2023), the most commonly reported adverse effects of retatrutide include: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (most frequent, particularly during dose escalation) Injection site reactions: Redness, bruising, or mild discomfort Decreased appetite: Generally considered a therapeutic effect but can contribute to nutritional deficiency if severe Increased heart rate: Observed with glucagon receptor agonism
Paik JM
If thats the case, start by taking half a stick pack for a few days to help your digestive system adjust to the increased fiber
How retatrutide compares to other weight loss peptides Context helps you understand where retatrutide fits within the broader weight loss peptide landscape
However, even though Novo has the first-mover advantage and market dominance, Eli Lillys drugs offer superior weight loss (Eli Lilly: ~20% vs
Rev Endocrine Metab Disord (2022) 23(3):52139